• No humanized monoclonal antibody was available to study heparin-induced thrombocytopenia (HIT).
Introduction
Heparin-induced thrombocytopenia (HIT) is a frequent drug-adverse event caused in most patients by plateletactivating antibodies (Abs) directed against complexes of heparin (H) bound to platelet factor 4 (PF4) [1, 2] . Most HIT Abs are immunoglobulins G (IgG), and are potentially pathogenic because they can activate platelets with heparin via FccRIIA receptors. The diagnosis of HIT is based on clinical and pathological criteria. The first category of laboratory HIT tests commonly used is immunologic and detects the binding of Abs to PF4 immobilized with heparin or polyvinyl sulfonate. The second category of assays is functional, more specific for pathogenic IgG Abs, and therefore is necessary for confirming the diagnosis of HIT in many patients. Nevertheless, these functional assays require strict quality controls (i.e. testing a weak positive HIT serum and using an appropriate negative control, as well as checking that platelet activation is inhibited by a high heparin concentration) [3] . Functional assays performed with platelet-rich plasma (PRP) or whole blood are less sensitive than methods with washed platelets such as serotonin release assay, with a high frequency of false-negative results [4, 5] . In addition, despite improvements in HIT laboratory assays, a standard is still lacking for both immunological and functional assays.
In addition, platelets from healthy donors also show wide variability in response to HIT antibodies, and HIT does not develop in many patients with significant levels of antibodies against PF4/H. The mechanisms that regulate the pathogenicity of HIT antibodies have not been fully defined, although recent studies found that variations in CD148, FCGR2A and UBASH3B genes might have a significant effect on platelet activation induced by HIT antibodies [6] [7] [8] . Several studies of the pathophysiology of HIT involved KKO, a murine monoclonal anti-PF4/H antibody that activates platelets and monocytes by cross-linking FccRIIA and behaves like human HIT IgG [9] [10] [11] [12] . However, KKO is an IgG2b antibody, a subclass absent in humans [13] . Moreover, IgG anti-PF4/H antibodies present in HIT plasma samples are predominantly IgG1. Also, human and mouse Fcc receptors (FccRs) have shown large differences in binding abilities [13] . Indeed, mouse FccRs efficiently bind human IgG subclasses, whereas human FccRs do not or poorly bind mouse IgG subclasses.
FccR-IgG interactions are highly critical in the pathogenesis of HIT [14] , so we aimed to develop a monoclonal anti-PF4/H antibody with a human Fc fragment by using transgenic mice homozygous for the Cc gene of a G-class human immunoglobulin that directly produce chimeric IgG1 antibodies. We then studied the characteristics of the obtained monoclonal antibody, 5B9, and demonstrated that it fully mimicked the cellular effects of human HIT antibodies.
Materials and methods

Development of monoclonal antibodies to PF4/heparin complex
To develop an anti-PF4/H antibody with a human Fc fragment, we used transgenic Balb/c mice homozygous for the Cc gene of a G-class human immunoglobulin that produce chimeric IgG1 antibodies composed of murine light chains and chimeric heavy chains with a murine variable region and a human constant region (GammaPrim TM , B Cell Design, Limoges, France). Four 6-to 8-week-old mice were injected intraperitoneally on day 0 with a 50-lL sterile solution of phosphate buffer saline (PBS, SigmaAldrich, Saint-Quentin Fallavier, France) containing purified human PF4 (50 lg, Hyphen BioMed, Neuvillesur-Oise, France), unfractionated heparin (UFH 2 IU; Heparin Choay; Sanofi) and 25 lL Freund's complete adjuvant [15] . Then, the same preparation containing preformed PF4/heparin complexes in PBS with Freund's complete adjuvant was injected intraperitoneally or through the tail vein in mice on days 15 and 30. Finally, 10 days after the later injection, a boost of human PF4/heparin complexes in PBS with Freund's incomplete adjuvant was injected intravenously into all mice 3 days before they were sacrificed. The synthesis of anti-PF4/heparin antibodies was monitored using a homemade ELISA, adapted from Arepally et al. [15] with microplates coated with purified human PF4 (2.5 lg mL
À1
, Hyphen Biomed) with or without 0.05 IU mL À1 of heparin. Three mice positive for anti-PF4/H antibodies were killed and their spleens were removed for fusion procedures. Hybridomas were then obtained from chemical fusion of B cells with SP2/0 AG14 myeloma cells using a method adapted from K€ olher and Milstein [16] . Hybridomas were cultured for 13 days, and supernatants screened by ELISA to detect antibodies to PF4/H and PF4. Wells considered positive were then subcloned by limiting dilutions, and positive ELISA results were confirmed for eight clones. Finally, four clones were isolated: three produced antibodies that equally bound PF4/H complex and PF4 alone on ELISA (1C12, 1E12 and 2E1; Figure S1 ). The other clone produced an IgG1 named 5B9 that was mainly specific to PF4/H and was isolated from ascitic fluid by using affinity columns. The reactivity of 5B9 was evaluated with three commercial IgG-specific ELISAs (Asserachrom HPIA IgG, Stago, Asnieres, France; Zymutest HIA IgG, Hyphen Biomed; PF4 IgG, Immucor GTI, Waukesha, WI, USA) involving different antigen targets with modified PF4 (PF4/H, PF4/H/protamine and PF4/polyvinyl sulfonate complexes, respectively).
Platelet activation and aggregation tests
Whole blood from healthy donors was collected after informed consent in acid-citrate-dextrose supplemented with prostaglandin E1 (0.1 mM, Sigma-Aldrich), according to the Helsinki Declaration principles and International Society on Thrombosis and Haemostasis recommendations [17] . Platelets were washed and suspended at a final count adjusted to 350 G L
À1
. In addition, whole blood from healthy donors was collected in 0.129 M sodium citrate and PRP was isolated. Platelet aggregation tests (PATs) with PRP and washed platelets were performed in an APACT 4 aggregometer (ELITech Group, Puteaux, France) with different concentrations of 5B9 (50, 20 and 10 lg mL À1 ) and heparin (0, 0.5 and 50 IU mL
). Serotonin release assays (SRAs) were performed [18] , with the same concentrations of 5B9, with or without addition of exogenous PF4 (10 lg mL
).
Assays of tissue factor mRNA levels after stimulation by 5B9 antibody Monocytes were isolated from whole blood collected from healthy donors in 0.129 M sodium citrate with the Monocyte Isolation Kit II (Miltenyi Biotec, Paris, France) [11] . P24 plates were seeded with 5 9 10 5 cells/well and various concentrations of purified human PF4 and heparin were then added, followed by the addition of 5B9 (20 lg mL À1 ). After incubation at 37°C for 2 h, total RNA was isolated using the RNeasy Mini kit (Qiagen, Courtaboeuf, France) and mRNA levels specific for tissue factor (TF) and CD14 genes were measured by qPCR as described [7] .
Human neutrophil degranulation assay
Blood neutrophils were isolated as described [19] . After priming with cytochalasin B (5 lg mL À1 ) and human tumour necrosis factor a (10 ng mL À1 ), neutrophils (10 6 cells for each assay) were stimulated with various concentrations of heparin, human PF4 (5 lg mL À1 ) and 5B9
(20 lg mL À1 ), or phorbol myristate acetate (100 ng mL À1 , Sigma-Aldrich) as positive control. After incubation for 90 min, supernatants were collected and neutrophil activation was assessed by using a fluorogenic substrate of neutrophil proteases (Abz-HPV-PVYAFSPQ-Yno2, 25 lM, GeneCust Europe, Ellange, Luxembourg) [19] . For each condition, maximal hydrolysis speed of the substrate (Vmax) was measured and ratio of values under stimulated and basal conditions were calculated.
Stimulation of human whole blood with 5B9 antibody
Whole blood from healthy donors in 0.129 M sodium citrate was incubated for 60 min with 5B9 (20 lg mL
À1
), with and without heparin (0.5 IU mL À1 ), at 37°C. After centrifugation, plasma was collected and clotting time was measured with the Procoag-PPL assay (Stago), which is sensitive to the presence of phospholipid microparticles [7] . Total RNA was isolated from cells using the Qiamp RNA blood Mini kit (Qiagen) and mRNA levels from TF and CD14 genes were measured by qPCR.
ELISA competition assays
The ability of 5B9 and KKO to bind PF4/H-coated wells in the presence of plasma from patients with anti-PF4/H antibodies was evaluated using the Asserachrom HPIA Ò assay (Stago) with modification. Diluted plasmas were first incubated for 50 min at room temperature (RT) in wells coated with PF4/H complex. Then, 5B9 or KKO was added to wells without removing diluted plasma samples and incubated for 10 min at RT. The concentrations of 5B9 and KKO used (10 and 0.7 lg mL
À1
, respectively) were defined in specific ELISA experiments and provided 75% of the maximal binding of each antibody to PF4/H complexes. After washings, alkaline-phosphatase-conjugated goat anti-murine j chain (1/500; Jackson ImmunoResearch, Newmarket, UK) was added and incubated for 1 h at RT. After washings, pNPP substrate was added, and the reaction was stopped with NaOH 3N before absorbances were read at 405 nm. ). Finally, 5B9 binding was revealed using an anti-human Fc antibody.
In vivo effects of 5B9 in HIT mouse model
All studies in mice were conducted in accordance with the guidelines and approval of the Institutional Animal Care and Use Committees of Thomas Jefferson University and Portola Pharmaceuticals. Both facilities are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. The transgenic HIT mice (human FcγRIIA, hPF4-transgenic, mPF4 knockout) were assigned to two groups receiving 5B9 or KKO. At day 0, platelet counts were obtained for baseline. Mice were injected with KKO (30 lg g À1 bodyweight, intraperitoneally; n = 3) or 5B9 (15.8 lg g
À1
; n = 3) on day 0. At days 1, 2 and 3, 1400 U kg À1 heparin were injected subcutaneously using 28G " needles, then 4 h later platelets were counted by using a Hemavet Analyser (model 850, CDC Technologies, Oxford, CT, USA) and monitored over time to assess thrombocytopenia. The level of the thrombin-antithrombin complex (TAT) was also measured as a marker of thrombin generation in vivo by using ELISA as previously described [20] .
Docking analysis of 5B9-PF4 complex 5B9 cDNA was sequenced using the Sanger method, and a model of the 3D structure of 5B9 antibody was then built by using MODELLER [21] . The structures used as templates for homology modelling were PDB:1F58 for the variable heavy (VH) chain and constant domains and PDB:5B9L for the variable light (VL) chain. The resulting 3D model was docked on PF4 complexed with fondaparinux (PDB:4R9W) [22] , using the method PRIOR optimized for antibody/antigen complexes [23] . The models for the assembly of heparin, three tetramers of PF4 and three antibodies were built manually, with the structure of heparin heptasaccharide (PDB:1SR5) used as a guide. Structures were imaged using the PyMOL Graphics System (v1.8, Schr€ odinger LLC, New York, NY, USA).
Statistical analysis
The Student t-test was used to compare data obtained after stimulating monocytes, neutrophils or whole blood with 5B9 and during studies in vivo. P < 0.05 was considered statistically significant.
Results
5B9 specifically binds to PF4/H complexes
Homemade ELISA revealed that 5B9 mostly bound to the PF4/H complex with no significant interaction with PF4 alone (Fig. 1A) . Also, the binding of 5B9 to PF4/H complex was optimal with concentrations of UFH and PF4 of 0. (Fig. 1C) .
5B9 induces heparin-dependent platelet activation and aggregation
5B9 induced heparin-dependent platelet activation with maximal release of 14 C serotonin achieved with 0.1 IU mL À1 UFH, which was similar to the pattern observed with most of the HIT plasma samples ( Fig. 2A) . As expected, platelets were not activated by 5B9 when heparin was absent or was present at a high concentration (10 IU mL
À1
). With exogenous PF4 (10 lg mL À1 ) in the reaction mixture, 5B9 induced strong platelet activation without requiring heparin, but with complete inhibition with 10 IU mL À1 UFH (Fig. 2B) . The release of serotonin was always inhibited by the monoclonal IV.3 antibody whatever the conditions, with or without exogenous PF4. 5B9 also induced heparin-dependent platelet aggregation with PRP and washed platelets from healthy donors. This response ( 
5B9 induces monocyte and neutrophil activation
5B9 with exogenous PF4 (5 lg mL
À1
) increased tissue factor mRNA synthesis from isolated monocytes, an effect that was potentiated by a low concentration of UFH (0.1 IU mL
) and fully inhibited by 10 IU mL À1 UFH (Fig. 3A) . In addition, after incubation of whole blood from healthy donors with 5B9 and UFH (0.5 IU mL À1 ), the TF mRNA level was 3.2-fold increased compared with without heparin (P < 0.05), and this effect was inhibited by a high concentration of heparin (50 IU mL À1 ) (Fig. 3B ).
This TF gene induction was associated with procoagulant activity because plasma clotting time was shortened after incubation of whole blood with 5B9 and UFH (39 vs. 60 s without UFH; Fig. 3C ). Also, 5B9 incubated with PF4 and without UFH led to strong release of protease activity from isolated neutrophils (with a 5.9-fold increase in maximal hydrolysis speed compared with the non-stimulated condition) (Fig. 3D) . However, this effect was potentiated (8.9-fold) by a low UFH concentration (0.1 IU mL À1 ) and inhibited with 10 IU mL À1 UFH.
5B9 induces thrombocytopenia in the hFccRIIA/hPF4 transgenic mouse model
In vivo, 5B9 injected with UFH at 15.8 lg g À1 in transgenic mice expressing human FccRIIA and PF4 induced thrombocytopenia with a 38-40% decrease in platelet count as compared with the basal value (Fig. 4A ). This effect of 5B9 was similar to that obtained with KKO injected at 30 lg/g (decrease in platelet count between 29% and 35%). Plasma level of TAT was measured at times that coincided with platelet nadirs in each experimental group. TAT plasma levels significantly increased after injection of UFH in all treated mice, but this effect was more pronounced on day 1 with 5B9 (mean 47 vs. 5 ng mL
at day 0) than with KKO (33 vs. 11 ng mL À1 ). This difference was no longer observed 2 days after injection of UFH, but TAT levels remained high in all mice studied (36 and 33 ng mL À1 with 5B9
and KKO, respectively).
5B9 binds an epitope close to that recognized by human HIT antibodies
Cross-competition experiments were performed to determine whether 5B9 and pathogenic HIT antibodies could recognize overlapping epitopes in the PF4/H complex. The binding of 5B9 to PF4/H complexes was inhibited (i.e. inhibition > 20%) by 60% of HIT plasma samples tested (15/25) and only 12% of plasma samples containing non-pathogenic anti-PF4/H antibodies (3/25) (Fig. 5A) . Noticeably, there was no significant difference in the main clinical (4Ts, thrombosis, treatment) and (Table S1 ). Similar cross-competition experiments were performed with KKO: its binding to the PF4/ H complex was inhibited by 32% of HIT plasma samples (8/25) and 0% of non-HIT samples. Levels of inhibition of 5B9 and KKO binding to PF4/H by HIT plasma samples were also highly correlated (R 2 = 0.85), which suggests that epitopes recognized by both antibodies are similar. In addition, competitive assays with KKO and 5B9 showed that KKO inhibited in a concentrationdependent manner the binding of 5B9 to the PF4/H complex, with absorbance varying from 2.05 without KKO to 0.55 with 20 lg mL À1 KKO (Fig. 5C ).
Modelling the 5B9 scFv/PF4 complex by docking After 5B9 cDNA was sequenced, we defined a docking model based on the V H and V L sequences of 5B9 (scFv) obtained, and with recently described data for the crystal structure of PF4 tetramer modified by fondaparinux [22] . According to this model, 5B9 appeared to bind B and D monomers of PF4 (Fig. 6A ) and this interaction could stabilize the PF4 tetramer and then macromolecular complexes composed of several PF4 tetramers bound to extended glycosaminoglycan chains (Fig. 6B) . The epitope of 5B9 was predicted to involve 24 amino acids, 12 in monomer B and 12 in monomer D. Comparatively, KKO mostly interacts with monomer B, with a binding site involving 22 residues including Gln9 and Val13-Thr15 (VKT) that are also recognized by 5B9 (Fig. 6C and D) . Comparatively, KKO bound only seven amino acids of monomer D, but three of these (i.e. Gln9-Cys10 and Thr38) also appeared to contribute to the epitope of 5B9. Five other residues (i.e. Ala32-Pro34 or AGP and Cys36-Pro37), either in monomer B or monomer D, were also shown to interact with KKO and 5B9, respectively (Fig. 6D) . 
Discussion
In this study, we characterized the first chimeric monoclonal HIT antibody that contains a human Fc fragment, and showed that it behaves similarly to human IgG anti-PF4/H antibodies. 5B9 was obtained after injecting purified hPF4/H complexes into a transgenic mouse able to produce IgG antibodies with a human constant region. Among the clones obtained, only 5B9 produced an IgG1 antibody specific to the PF4/H complex with very low reactivity against PF4 alone. Two other HIT activating antibodies have previously been developed. The first is KKO, a monoclonal antibody that also mainly binds PF4/H complexes and, weakly, PF4 alone [15] . However, KKO is a murine IgG2 k antibody, a subclass absent in humans, and therefore does not interact with FccRs, similar to HIT human IgG antibodies. More recently, Asada et al. developed a monoclonal murine IgG1 antibody, but it bound PF4/H complex and PF4 alone similarly and induced platelet activation without heparin [24] .
Importantly, 5B9 was shown to induce heparin-and FccRIIA-dependent platelet activation similar to that observed with plasma samples from HIT patients, whether tested with PRP or washed platelets. We recently demonstrated that the platelet response to 5B9 widely varied among donors, particularly when testing PRP [7] . This variability was similar to that observed with human HIT plasma samples and probably explains the relatively low sensitivity of platelet aggregation tests for the diagnosis of HIT [25] . Hence, 5B9 may be used as a positive control in functional assays to determine whether healthy platelet donors are good or poor responders to HIT antibodies. In addition to activating platelets, 5B9 can also activate monocytes, inducing TF mRNA synthesis even in the absence of exogenous heparin, as previously reported [26, 27] , and procoagulant activity, which in vivo probably contributes to the risk of thrombosis [11, 28] . 5B9 also activates neutrophils with a significant release of a protease activity, which confirms previous data obtained with HIT plasma samples [29] , but the pathophysiological significance of this effect remains undefined.
When 5B9 was tested in ELISA, the concentration allowing about 75% of maximal binding was 10 lg mL À1 , although less than 1 lg mL À1 KKO was enough to achieve a similar binding. This finding suggests a lower affinity of 5B9 for the PF4/H complex than KKO. However, in functional assays, 20 lg mL À1 5B9
were sufficient to induce platelet activation with heparin, but without addition of exogenous PF4. Comparatively, 80 lg mL À1 KKO were used to induce heparin-dependent platelet activation with 10 lg mL À1 PF4 [15, 30] . Our in vivo experiments also demonstrated that 5B9 induced thrombocytopenia after intravenous injection with heparin in transgenic mice expressing human FccRIIA and PF4, an effect similar to that obtained with a higher dose of KKO. In addition, the thrombin-antithrombin level, validated as a surrogate marker of thrombosis in patients with HIT [31] and of thrombosis in mouse models [32, 33] , was significantly higher in mice that had received 5B9 than in those injected with KKO. The class of 5B9 and KKO and the origin of their Fc portion are not the same, these variations probably explaining differences in platelet reactivity to these IgG antibodies in vitro and in vivo. 5B9 is indeed composed of murine light chains and chimeric heavy chains with a murine variable region and a human IgG1 constant region, and IgG1 is the most frequently represented IgG subclass among human HIT antibodies [4, 34] . In contrast, KKO is a full murine IgG2b k , a class absent in our species, and weakly binds human FccRIIA. Indeed, the affinity of murine IgG2b for the human FccRIIA receptor is very low (association constants or K A = 1.2 and 0.9 9 10 5 M À1 for 131H and 131R isoforms, respectively)
as compared with that of human IgG1 (5.2 and 3.5 9 10 5 M À1 ) [35] . Moreover, Fc receptors other than
FccRIIA probably contribute to the pathogenic effects of HIT antibodies [14] , particularly FccRIIIA, which does not bind murine IgG2b [36] . In contrast, human IgG1 subclass shows relatively high affinity (K A > 10 6 ) for this receptor [37] and an association between FccRIIIA V158F polymorphism and the risk of HIT was previously demonstrated in patients with a high titre of anti-PF4/H antibodies [38] .
In clinical practice, anti-PF4 antibodies in HIT patients are detected by different immunoassays based on variable PF4 complexes. 5B9 appeared to react similarly with PF4 bound to heparin (Stago assay) or polyvinyl sulfonate, a non-heparin polyanion (Immucor GTI assay), but its binding to modified PF4 seemed lower when evaluated by the Hyphen BioMed assay. In this assay, PF4 (and probably other heparin-binding antigenic proteins) is provided by a platelet lysate, and binds to heparin immobilized by protamine during the incubation step. Therefore, 5B9 (as well as human HIT antibodies) probably interacts differently with PF4 modified by protamine-bound heparin (i.e. in the Hyphen BioMed assay) and PF4/H or PF4/PVS complexes used as antigens in the other methods. We also showed that 5B9 mainly bound to PF4 modified by heparin, and this binding was strongly reduced by a high concentration of heparin, similar to findings with KKO [15] or most HIT human antibodies [39] .
Importantly, 5B9 binding to PF4/H complexes was decreased by human antibodies present in 15/25 HIT plasma samples, but this inhibitory effect was obtained with only three of 25 samples containing non-activating human anti-PF4/H antibodies. Hence, human HIT pathogenic antibodies may bind PF4 epitopes that are close to those recognized by 5B9, but different from those targeted by non-platelet-activating antibodies. In similar experiments with KKO, we found no significant inhibition of this antibody binding to PF4/H in the presence of non-pathogenic anti-PF4/H antibodies, but a significant inhibitory effect with eight of 25 HIT plasma samples. These results agree with those from Cuker et al. [40] , and confirm that the KKO binding site on modified PF4 proabably overlaps epitopes recognized by some of the pathogenic antibodies in HIT patients.
Several HIT human antibodies also decreased significantly the binding of both 5B9 and KKO to the PF4/H complex. Moreover, high concentrations of KKO also strongly inhibited 5B9/PF4 interaction. Accordingly, our predictive docking model suggested that the epitopes of 5B9 and KKO largely overlap. However, differences in these epitopes, notably because 5B9 seems to bind to both B and D monomers whereas KKO mostly interacts with the B monomer [22] , could explain some of the variation observed in ELISA competitive assays performed with both antibodies and HIT plasma samples. Several of these residues, including Pro34, Pro37 and the sequence Asp7-Gln9, were previously found to be critical in the epitopes recognized by human HIT antibodies [41] and KKO [42] . Also, the amino-acid region that binds both KKO and 5B9 is likely to be important in promoting heparin-dependent platelet activation and thrombocytopenia. As recently demonstrated, KKO stabilizes the ternary complex KKO/PF4/H [22] and initiates the oligomerization of PF4 tetramers [43] . Our functional studies also strongly suggest that like KKO, 5B9 probably also favors the formation of ultra-large immune complexes on cell surfaces, a prerequisite for potent FccRIIA-dependent cell activation.
Our docking model was developed based on data obtained after crystallization of KKO Fab with PF4 and fondaparinux, which is a homogeneous molecule. We therefore cannot exclude the possibility that therapeutic glycosaminoglycans other than fondaparinux are inducing other changes in PF4 antigenicity [44] .
In conclusion, 5B9 is the first monoclonal antibody specific to PF4-heparin complex with a human Fc fragment, and could be used as a positive control and standard reagent for laboratory HIT assays. Moreover, 5B9 fully mimics the effects of human antibodies and hence could be a useful specific tool when studying FccR-dependent cell activation in the pathophysiology of HIT. 
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